Collagen peptide supplier Gelita AG (Eberbach, Germany) has opened a biotechnology center in Frankfurt am Main. At this site, the company uses biotechnology to develop and optimize microorganisms to produce a wide range of organic compounds. To start, the company is focused on using biotechnology to develop proteins for the food, cosmetics, pharmaceutical and medical industries.
“Biotechnology overcomes the limitations of conventional manufacturing processes,” said the site’s laboratory director, Christoph Schorsch, PhD, in a press release. “Proteins produced through biotechnology allow us to manufacture alternatives of consistently high quality and with optimized properties, in some cases even more resource-efficient and sustainable than conventional means.
The location of the site in Frankfurt is close to research industries and the biotechnology industry, with the anticipation of attracting well-trained and experienced specialists.
The company says its investment in biotech represents its mission to create a “broader and more sustainable product portfolio.”
“Investing in Gelita’s Biotech Hub is a clear commitment to biotechnology, a key and forward-looking element 21sta core technology that offers enormous potential for innovation,” said Sven Abend, PhD, CEO of Gelita AG, during the site opening ceremony. “This allows us to respond sustainably and with new offers to the growing demand from international markets. At the same time, the new research laboratory underlines our desire to innovate in our markets and our objective of sustainable and profitable growth.